PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL
Diffuse Large B-cell Lymphoma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 240 (final count)
- Started
- Aug 20, 2020
- Main results expected
- Jan 23, 2026
- Fully finished
- Dec 31, 2026
- Results posted
- Oct 21, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival (OS)
Measured over: From the date of randomization until date of death or censoring date, whichever occurred first (maximum up to 50 months)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04404283 · record last updated 2026-10-21 · checked 2026-11-09 15:36 UTC